China Pharma Holdings (CPHI) Non-Current Deferred Tax Liability (2010 - 2026)

China Pharma Holdings (CPHI) has reported Non-Current Deferred Tax Liability for 17 consecutive years, with $771730.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Deferred Tax Liability rose 5.11% year-over-year to $771730.0; the trailing twelve-month figure through Jun 2026 stood at $771730.0 (up 5.11% YoY), and the FY2025 full-year result was $747805.0, up 2.27% from the prior year.
• Non-Current Deferred Tax Liability climbed to $771730.0 in Q2 2026 per CPHI's latest filing, from $759628.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $827978.0 in Q1 2022 and bottomed at $727417.0 in Q2 2023.
• Historically, Non-Current Deferred Tax Liability has averaged $750983.8 across 5 years, with a median of $741471.0 in 2023.
• The sharpest annual moves came in 2022 and 2026: Non-Current Deferred Tax Liability retreated 8.65% in 2022, then increased 5.11% in 2026.
• Over 5 years, Non-Current Deferred Tax Liability stood at $754698.0 in 2022, then dropped by 1.67% to $742114.0 in 2023, then decreased by 1.47% to $731202.0 in 2024, then rose by 2.27% to $747805.0 in 2025, then rose by 3.2% to $771730.0 in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $771730.0, $759628.0, and $747805.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.